Action of resveratrol alone or in combination with roscovitine, a CDK inhibitor, on cell cycle progression in human HL-60 leukemia cells

Biochemical Pharmacology

Volumn 76, Issue 11, 2008, Pages 1554-1562

  Komina, Oxana ^a   Wesierska Gadek, Józefa ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Apoptosis; Cell cycle arrest; G1 arrest; HL 60 promyelocytic leukemia cells; Nutrition supplements; Polyphenol

Indexed keywords

CASPASE 3; PROTEIN P53; RESVERATROL; ROSCOVITINE;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL STRAIN HL 60; CELL STRAIN MCF 7; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASES; FLOW CYTOMETRY; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PURINES; STILBENES;

EID: 55949119791     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.08.002     Document Type: Article

References (38)

1. Dorai T., and Aggarwal B.B. Role of chemopreventive agents in cancer therapy. Cancer Lett 215 (2004) 129-140
2. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275 (1997) 218-220
3. Aggarwal B.B., and Shishodia S. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol 71 (2006) 1397-1421
4. Le Corre L., Chalabi N., Delort L., Bignon Y.J., and Bernard-Gallon D.J. Resveratrol and breast cancer chemoprevention: molecular mechanisms. Mol Nutr Food Res 49 (2005) 462-471
5. Signorelli P., and Ghidoni R. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J Nutr Biochem 16 (2005) 449-466
6. Saiko P., Szakmary A., Jaeger W., and Szekeres T. Resveratrol and its analogs: Defense against cancer, coronary disease and neurodegenerative maladies or just a fad. Mutat Res/Rev Mutat Res 658 (2008) 68-94
7. Athar M., Back J.H., Tang X., Kim K.H., Kopelovich L., Bickers D.R., et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 224 (2007) 274-283
8. Shankar S., Singh G., and Srivastava R.K. Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci 12 (2007) 4839-4854
9. Kang J.H., Park Y.H., Choi S.W., Yang E.K., and Lee W.J. Resveratrol derivatives potently induce apoptosis in human promyelocytic leukemia cells. Exp Mol Med 35 (2003) 467-474
10. Lee S.H., Ryu S.Y., Kim H.B., Kim M.Y., and Chun Y.J. Induction of apoptosis by 3,4′-dimethoxy-5-hydroxystilbene in human promyeloid leukemic HL-60 cells. Planta Med 68 (2002) 123-127
11. Clement M.V., Hirpara J.L., Chawdhury S.H., and Pervaiz S. Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood 92 (1998) 996-1002
12. Asou H., Koshizuka K., Kyo T., Takata N., Kamada N., and Koeffier H.P. Resveratrol: a natural product derived from grapes, is a new inducer of differentiation in human myeloid leukemias. Int J Hematol 75 (2002) 528-533
13. Ragione F.D., Cucciolla V., Borriello A., Pietra V.D., Racioppi L., Soldati G., et al. Resveratrol arrests the cell division cycle at S/G2 phase transition. Biochem Biophys Res Commun 250 (1998) 53-58
14. Jang M., and Pezzuto J.M. Cancer chemopreventive activity of resveratrol. Drugs Exp Clin Res 25 (1999) 65-77
15. Roberti M., Pizzirani D., Recanatini M., Simoni D., Grimaudo S., DiCristina A.D., et al. Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem 49 (2006) 3012-3018
16. Meijer L., Borgne A., Mulner O., Chong J.P., Blow J.J., Inagaki N., et al. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur J Biochem 243 (1997) 527-536
17. McClue S.J., Blake D., Clarke R., Cowan A., Cummings L., Fischer P.M., et al. In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine). Int J Cancer 102 (2002) 463-468
18. Schang L.M., Bantly A., Knockaert M., Shaheen F., Meijer L., Malim M.H., et al. Pharmacological cyclin-dependent kinase inhibitors inhibit replication of wild-type and drug-resistant strains of herpes simplex virus and human immunodeficiency virus type 1 by targeting cellular, not viral, proteins. J Virol 76 (2002) 7874-7882
19. Wang D., de la Fuente C., Deng L., Wang L., Zilberman I., Eadie C., et al. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J Virol 75 (2001) 7266-7279
20. Smith P.J., and Yue E.W. Inhibitors of cyclin-dependent kinases as anti-tumor agents (2007), CRC/Taylor & Francis, Boca Raton
21. Fischer P.M., and Gianella-Borradori A. Recent progress in the discovery and development of cyclin-dependent kinase inhibitors. Expert Opin Invest Drugs 14 (2005) 457-477
22. Guzi T. CYC-202 Cyclacel. Curr Opin Invest Drugs 5 (2004) 1311-1318
23. MacCallum D.E., Melville J., Frame S., Watt K., Anderson S., Gianella-Borradori A., et al. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1. Cancer Res 65 (2005) 5399-5407
24. Lacrima K., Valentini A., Lambertini C., Taborelli M., Rinaldi A., Zucca E., et al. In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. Ann Oncol 16 (2005) 1169-1176
25. Edamatsu H., Gau C.L., Nemoto T., Guo L., and Tamanoi F. Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene 19 (2000) 3059-3068
26. Payton M., Chung G., Yakowec P., Wong A., Powers D., Xiong L., et al. Discovery and evaluation of dual CDK1 and CDK2 inhibitors. Cancer Res 66 (2006) 4299-4308
27. Inoue S., Walewska R., Dyer M.J.S., and Cohen G.M. Downregulation of Mcl-1 potentiates HDACi-mediated apoptosis in leukemic cells. Leukemia (2008)
28. Wesierska-Gadek J., Kramer M.P., and Maurer M. Resveratrol modulates roscovitine-mediated cell cycle arrest of human MCF-7 breast cancer cells. Food Chem Toxicol (2007)
29. Wojciechowski J., Horky M., Gueorguieva M., and Wesierska-Gadek J. Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Int J Cancer 106 (2003) 486-495
30. Wesierska-Gadek J., Gueorguieva M., and Horky M. Dual action of cyclin-dependent kinase inhibitors: induction of cell cycle arrest and apoptosis. A comparison of the effects exerted by roscovitine and cisplatin. Pol J Pharmacol 55 (2003) 895-902
31. Wesierska-Gadek J., Gueorguieva M., and Horky M. Roscovitine-induced up-regulation of p53AIP1 protein precedes the onset of apoptosis in human MCF-7 breast cancer cells. Mol Cancer Ther 4 (2005) 113-124
32. Wesierska-Gadek J., and Schmid G. Overexpressed poly(ADP-ribose) polymerase delays the release of rat cells from p53-mediated G(1) checkpoint. J Cell Biochem 80 (2000) 85-103
33. Vindelov L.L., Christensen I.J., and Nissen N.I. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3 (1983) 323-327
34. Wesierska-Gadek J., Schmitz M.L., and Ranftler C. Roscovitine-activated HIP2 kinase induces phosphorylation of wt p53 at Ser-46 in human MCF-7 breast cancer cells. J Cell Biochem 100 (2007) 865-874
35. Pan J., Zou J., Wu D.Y., Roberson R.S., Hennings L.J., Ma X., et al. TLS-ERG leukemia fusion protein deregulates cyclin-dependent kinase 1 and blocks terminal differentiation of myeloid progenitor cells. Mol Cancer Res 6 (2008) 862-872
36. Wolf D., and Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proc Natl Acad Sci USA 82 (1985) 790-794
37. Raynaud F.I., Whittaker S.R., Fischer P.M., McClue S., Walton M.I., Barrie S.E., et al. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 11 (2005) 4875-4887
38. Benson C., White J., De Bono J., O'Donnell A., Raynaud F., Cruickshank C., et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 96 (2007) 29-37